An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
Latest Information Update: 28 Jun 2023
At a glance
- Drugs PEC QT (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors CRISPR Therapeutics
Most Recent Events
- 23 Jun 2023 Status changed from active, no longer recruiting to completed.
- 21 Feb 2023 According to a CRISPR Therapeutics media release, dosing has been completed in this trial.
- 22 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Apr 2023.